Dataset Information

Multiple ?-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects.

ABSTRACT:

Background

Alcadein? (Alc?) is a neuronal membrane protein that colocalizes with the Alzheimer's amyloid-? precursor protein (APP). Successive cleavage of APP by ?- and ?-secretases generates the aggregatable amyloid-? peptide (A?), while cleavage of APP or Alc? by ?- and ?-secretases generates non-aggregatable p3 or p3-Alc? peptides. A? and p3-Alc? can be recovered from human cerebrospinal fluid (CSF). We have previously reported alternative processing of APP and Alc? in the CSF of some patients with sporadic mild cognitive impairment (MCI) and AD (SAD).

Results

Using the sandwich enzyme-linked immunosorbent assay (ELISA) system that detects total p3-Alc?, we determined levels of total p3-Alc? in CSF from subjects in one of four diagnostic categories (elderly controls, MCI, SAD, or other neurological disease) derived from three independent cohorts. Levels of A?40 correlated with levels of total p3-Alc? in all cohorts.

Conclusions

We confirm that A?40 is the most abundant A? species, and we propose a model in which CSF p3-Alc? can serve as a either (1) a nonaggregatable surrogate marker for ?-secretase activity; (2) as a marker for clearance of transmembrane domain peptides derived from integral protein catabolism; or (3) both. We propose the specification of an MCI/SAD endophenotype characterized by co-elevation of levels of both CSF p3-Alc? and A?40, and we propose that subjects in this category might be especially responsive to therapeutics aimed at modulation of ?-secretase function and/or transmembrane domain peptide clearance. These peptides may also be used to monitor the efficacy of therapeutics that target these steps in A? metabolism.

SUBMITTER: Hata S

PROVIDER: S-EPMC3422204 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects.

Hata Saori S Taniguchi Miyako M Piao Yi Y Ikeuchi Takeshi T Fagan Anne M AM Holtzman David M DM Bateman Randall R Sohrabi Hamid R HR Martins Ralph N RN Gandy Sam S Urakami Katsuya K Suzuki Toshiharu T

Molecular neurodegeneration 20120425

<h4>Background</h4>Alcadeinα (Alcα) is a neuronal membrane protein that colocalizes with the Alzheimer's amyloid-β precursor protein (APP). Successive cleavage of APP by β- and γ-secretases generates the aggregatable amyloid-β peptide (Aβ), while cleavage of APP or Alcα by α- and γ-secretases generates non-aggregatable p3 or p3-Alcα peptides. Aβ and p3-Alcα can be recovered from human cerebrospinal fluid (CSF). We have previously reported alternative processing of APP and Alcα in the CSF of some ...[more]

PMID: 22534039

Similar Datasets

Project description:Alzheimer's disease brains are characterized by extracellular plaques containing the aggregated amyloid ?42 (A?42) peptide and intraneuronal tangles containing hyperphosphorylated tau. A?42 is produced by sequential processing of the amyloid precursor protein (APP) by ?-secretase followed by ?-secretase. Substantial efforts have been put into developing pharmaceuticals preventing the production or increasing the clearance of A?42. However, treatments inhibiting ?-secretase have proven disappointing due to off-target effects. To circumvent these effects, ?-secretase modulators (GSMs) have been developed, which rather than inhibiting ?-secretase shift its preference into producing less aggregation-prone shorter A? peptides. Belonging to the same family of proteins as APP, amyloid-like protein 1 (APLP1) is also a substrate for ?-secretase. Herein we investigated whether the GSM E2012 affects APLP1 processing in the central nervous system by measuring APLP1 peptide levels in cerebrospinal fluid (CSF) before and after E2012 treatment in dogs.An in-house monoclonal APLP1 antibody, AP1, was produced and utilized for immunopurification of APLP1 from human and dog CSF in a hybrid immuno-affinity mass spectrometric method. Seven dogs received a single dose of 20 or 80 mg/kg of E2012 in a randomized cross-over design and CSF was collected prior to and 4, 8 and 24 hours after dosing.We have identified 14 CSF APLP1 peptides in humans and 12 CSF APLP1 peptides in dogs. Of these, seven were reproducibly detectable in dogs who received E2012. We found a dose-dependent relative increase of the CSF peptides APLP1?17, 1?18 and 1?28 accompanied with a decrease of 1?25 and 1?27 in response to E2012 treatment. All peptides reverted to baseline over the time of sample collection.We show an in vivo effect of the GSM E2012 on the processing of APLP1 which is measurable in CSF. These data suggest that APLP1 peptides may be used as biomarkers to monitor drug effects of GSMs on ?-secretase processing in clinical trials. However, this requires further investigation in larger cohorts, including studies in man.

Project description:In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.